Highlights Kronos Bio, Inc.

Equities

KRON

US50107A1043

Market Closed - Nasdaq Other stock markets 21:00:00 14/05/2024 BST			5-day change	1st Jan Change
0.9995 ^USD	-2.01%		-4.81%	-20.04%

05-09	Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M	MT
05-09	Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M	05-09	MT
Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M	03-21	MT
Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
Kronos Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Kronos Bio, Inc. Announces to Assess KB-0742 At Planned New Dose Schedule in Ongoing Phase 1/2 Study	03-07	CI
Kronos Bio, Inc. Announces Pipeline Update and p300 KAT Inhibitor Development Candidate	12-18	CI
Earnings Flash (KRON) KRONOS BIO Reports Q3 Revenue $917,000	11-13	MT
Kronos Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Kronos Bio to Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 Kb-0742 Study At the Connective Tissue Oncology Society Annual Meeting	27/10/23	CI
Kronos Bio, Inc. Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC	13/10/23	CI
Earnings Flash (KRON) KRONOS BIO Reports Q2 Revenue $1.9M	08/08/23	MT
Kronos Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $1.2M	10/05/23	MT
Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
KRONOS BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	15/03/23	AQ
Kronos Bio Enters Into Drug Discovery Project With Genentech; Shares Rise	09/01/23	MT
Kronos Bio, Inc. Enters Into Collaboration and License Agreement with Genentech, Inc	09/01/23	CI
Kronos Bio, Inc. Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology	09/01/23	CI
Kronos Bio, Inc. Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia Preclinical Models at American Society of Hematology Meeting	11/12/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kronos Bio, Inc.

Equities

KRON

US50107A1043

Highlights

Filters